19-398 - An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Status: openA Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Description
This is a phase 3 efficacy and safety study of Ravulizumab in adults with neuromyelitis optica spectrum disorder (NMOSD). The goal is to provide NMOSD patients another treatment option for their condition that reduces treatment burden while maintaining a comparable risk/benefit profile.
Sponsors
This trial is sponsored by Alexion Pharmaceuticals.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at +1 (251) 665-8375 or by email at dlwilliams@health.southalabama.edu.
